Article metrics

Download PDFPDF

Correspondence
A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options

 

Online download statistics by month:

Online download statistics by month: September 2015 to March 2024

AbstractFullPdf
Sep 20152805932
Oct 2015312114
Nov 20151263429
Dec 20151313922
Jan 201648409
Feb 201618204
Mar 20161183438
Apr 2016184914
May 20161731018
Jun 2016481418
Jul 201645387
Aug 201610830
Sep 20161866
Oct 2016352710
Nov 20161325418
Dec 201610126
Jan 201718198
Feb 20173115
Mar 20170218
Apr 20170225
May 20171196
Jun 20175134
Jul 201717176
Aug 2017262610
Sep 201753179
Oct 2017333416
Nov 2017434423
Dec 2017272710
Jan 201826264
Feb 201815145
Mar 201822205
Apr 201825255
May 201815162
Jun 201820205
Jul 201814143
Aug 201814142
Sep 201820207
Oct 201825259
Nov 201828282
Dec 201817173
Jan 201919194
Feb 201916147
Mar 201920168
Apr 201919173
May 201932318
Jun 2019777
Jul 2019665
Aug 2019121214
Sep 201912124
Oct 2019232310
Nov 201911112
Dec 201919196
Jan 202029297
Feb 202013136
Mar 202023237
Apr 2020668
May 202010104
Jun 202011108
Jul 202016161
Aug 2020663
Sep 202013136
Oct 2020556
Nov 202017178
Dec 202010105
Jan 20211199
Feb 202117170
Mar 202110107
Apr 2021555
May 202110106
Jun 202115144
Jul 20216610
Aug 202112129
Sep 2021764
Oct 20217614
Nov 20218814
Dec 202138387
Jan 202231312
Feb 202257578
Mar 202263616
Apr 202267676
May 2022626210
Jun 202274747
Jul 202262603
Aug 2022828011
Sep 202280778
Oct 2022494810
Nov 202242424
Dec 202245435
Jan 202361618
Feb 202360602
Mar 202368684
Apr 202342415
May 202356566
Jun 202355555
Jul 2023646311
Aug 202346467
Sep 2023765
Oct 20231192
Nov 2023662
Dec 20231096
Jan 2024883
Feb 202415134
Mar 20245410
Total40112597833